Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00744497
First received: August 29, 2008
Last updated: September 25, 2014
Last verified: September 2014
Results First Received: November 15, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Prostatic Neoplasms
Interventions: Drug: Placebo
Drug: Dasatinib
Drug: Docetaxel
Drug: Prednisone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 1930 participants were enrolled, and 1522 were randomized to a treatment group; 1518 received at least 1 dose of dasatinib (761) or placebo (757).

Reporting Groups
  Description
Placebo Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
Dasatinib Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily

Participant Flow:   Overall Study
    Placebo     Dasatinib  
STARTED     760 [1]   762 [1]
Received Treatment     757     761  
COMPLETED     43 [2]   39 [2]
NOT COMPLETED     717     723  
Withdrawal by Subject                 21                 17  
Death                 11                 7  
Lost to Follow-up                 4                 2  
Poor compliance/noncompliance                 9                 4  
No longer meets study criteria                 7                 3  
Disease progression                 307                 208  
Study drug toxicity                 68                 140  
Adverse event unrelated to study drug                 77                 122  
Patient requested to stop study drug                 64                 72  
Maximum clinical benefit                 141                 138  
Other                 8                 10  
[1] Randomized
[2] Remained on study drug



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who were randomized to receive any treatment

Reporting Groups
  Description
Placebo Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
Dasatinib Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
Total Total of all reporting groups

Baseline Measures
    Placebo     Dasatinib     Total  
Number of Participants  
[units: participants]
  760     762     1522  
Age, Customized  
[units: participants]
     
Younger than 65 years     263     251     514  
65 to younger than 75 years     323     333     656  
75 years or older     174     178     352  
Gender  
[units: participants]
     
Female     0     0     0  
Male     760     762     1522  
Race/Ethnicity, Customized  
[units: Participants]
     
Asian     56     55     111  
Native Hawaiian or Other Pacific Islander     1     1     2  
Black or African American     34     23     57  
White     645     656     1301  
Other     24     27     51  
Study-Specific Measure  
[units: Participants]
     
Bone disease only     286     307     593  
Visceral/nodal disease only     73     80     153  
Both bone and visceral/nodal disease     399     373     772  
No evidence of metastatic disease     2     2     4  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival: Time From Randomization to Date of Death   [ Time Frame: From randomization to death or date of last contact (maximum reached: 45 months) ]
  Hide Outcome Measure 1

Measure Type Primary
Measure Title Overall Survival: Time From Randomization to Date of Death
Measure Description Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.
Time Frame From randomization to death or date of last contact (maximum reached: 45 months)  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who were randomized to receive any treatment

Reporting Groups
  Description
Placebo Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
Dasatinib Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily

Measured Values
    Placebo     Dasatinib  
Number of Participants Analyzed  
[units: participants]
  760     762  
Overall Survival: Time From Randomization to Date of Death  
[units: Months]
Median ( 95% Confidence Interval )
  21.2  
  ( 20.0 to 23.4 )  
  21.5  
  ( 20.3 to 22.8 )  


Statistical Analysis 1 for Overall Survival: Time From Randomization to Date of Death
Groups [1] All groups
Method [2] Log Rank
P Value [3] 0.9009
Hazard Ratio (HR) [4] 0.99
95% Confidence Interval ( 0.87 to 1.13 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  Confidence intervals calculated using Brookmeyer and Crowley method. Analysis compared survival in arms by 2-sided, alpha=0.05 level, log-rank test, stratified by bisphosphonate intake (yes/no) and urinary N-telopeptide category (<60 vs ≥60 nmol/mmol creatinine) as defined at randomization. Null hypothesis was that survival was equal in both arms. Power calculations indicated that ≥858 deaths would lead to ≥90% power at 5% level for rejecting null hypothesis, given a true hazard ratio of 0.8.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  An interim analysis on survival was performed. Final P-value was adjusted using an alpha spending function.
[4] Other relevant estimation information:
  No text entered.



2.  Secondary:   Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)   [ Time Frame: At baseline and every 12 weeks thereafter to end of treatment, at end of treatment, and at follow-up (within 42 days of end of dosing) ]

3.  Secondary:   Time to First Skeletal-related Event (SRE)   [ Time Frame: From day of randomization to date of first SRE or to last SRE assessment, if subsequent cancer therapy begun or no SRE (maximum reached: 42 months) ]

4.  Secondary:   Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline   [ Time Frame: At baseline, prior to each docetaxel infusion (every 3 weeks) to end of treatment, at end of treatment, and at follow-up (within 14 days of end of dosing) ]

5.  Secondary:   Progression-free Survival (PFS)   [ Time Frame: From day of randomization to disease progression or death (or to last clinical assessment, if subsequent cancer therapy started or no progression or death) (maximum reached: approximately 43 months) ]

6.  Secondary:   Time to Prostate Specific Antigen (PSA) Progression   [ Time Frame: From randomization to date of first PSA measurement leading to confirmed PSA progression (or to last bone scan assessment, if no progression or if cancer therapy started) (maximum reached: 30 months) ]

7.  Secondary:   Percentage of Participants With a Reduction in Pain Intensity From Baseline   [ Time Frame: At baseline, prior to each docetaxel infusion (every 3 weeks), at end of treatment, and at follow-up (within 14 days of end of dosing) ]

8.  Other Pre-specified:   Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation   [ Time Frame: Continuously throughout study to >=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever shorter. ]

9.  Other Pre-specified:   Number of Participants With Adverse Events (AEs) of Special Interest   [ Time Frame: Continuously throughout study to >=30 days after last dose of study drug until resolution of drug-related toxicity, or when toxicity was deemed irreversible, whichever was shorter ]

10.  Other Pre-specified:   Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology   [ Time Frame: At baseline, within 3 days prior to each infusion of docetaxel (each cycle) and at end of treatment. If docetaxel is discontinued, every other cycle. ]

11.  Other Pre-specified:   Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes   [ Time Frame: At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle. ]

12.  Other Pre-specified:   Number of Participants With Abnormal Results in Urinalysis   [ Time Frame: At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle. ]

13.  Other Pre-specified:   Number of Participants by Maximal On-study Fridericia-corrected QTc Interval by Electrocardiogram   [ Time Frame: At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing ]

14.  Other Pre-specified:   Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval by Electrocardiogram   [ Time Frame: At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing ]

15.  Other Pre-specified:   Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) <40% and >=40%On-study by Echocardiogram   [ Time Frame: At baseline, approximately 12 weeks after start of treatment, and thereafter whenever clinically indicated ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
Dasatinib Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
Placebo Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily

Serious Adverse Events
    Dasatinib     Placebo  
Total, serious adverse events      
# participants affected / at risk     376/761 (49.41%)     317/757 (41.88%)  
Blood and lymphatic system disorders      
Haemorrhagic anaemia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Disseminated intravascular coagulation † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Neutropenia † 1    
# participants affected / at risk     19/761 (2.50%)     18/757 (2.38%)  
Agranulocytosis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Anaemia † 1    
# participants affected / at risk     21/761 (2.76%)     15/757 (1.98%)  
Febrile bone marrow aplasia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Febrile neutropenia † 1    
# participants affected / at risk     32/761 (4.20%)     27/757 (3.57%)  
Hypochromic anaemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Thrombocytopenia † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Normochromic normocytic anaemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Leukopenia † 1    
# participants affected / at risk     9/761 (1.18%)     7/757 (0.92%)  
Cardiac disorders      
Acute coronary syndrome † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Myocardial infarction † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Supraventricular tachycardia † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Angina pectoris † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Cardiac failure congestive † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Sick sinus syndrome † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Supraventricular tachyarrhythmia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Atrial flutter † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Cardiopulmonary failure † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Coronary artery disease † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Pericardial effusion † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Tachycardia † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Atrial fibrillation † 1    
# participants affected / at risk     8/761 (1.05%)     8/757 (1.06%)  
Cardiac failure † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Cardio-respiratory arrest † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Myocardial ischaemia † 1    
# participants affected / at risk     2/761 (0.26%)     2/757 (0.26%)  
Atrioventricular block second degree † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Cardiac disorder † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Acute myocardial infarction † 1    
# participants affected / at risk     3/761 (0.39%)     0/757 (0.00%)  
Arrhythmia † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Cardiac arrest † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Left ventricular dysfunction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Congenital, familial and genetic disorders      
Hydrocele † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Eye disorders      
Maculopathy † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Amaurosis fugax † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Gastrointestinal disorders      
Constipation † 1    
# participants affected / at risk     5/761 (0.66%)     10/757 (1.32%)  
Gastric haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Gastritis erosive † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Inguinal hernia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Stomatitis † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Dyspepsia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Enteritis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Haematemesis † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Nausea † 1    
# participants affected / at risk     14/761 (1.84%)     7/757 (0.92%)  
Upper gastrointestinal haemorrhage † 1    
# participants affected / at risk     3/761 (0.39%)     0/757 (0.00%)  
Ileus † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Abdominal pain upper † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Colitis † 1    
# participants affected / at risk     4/761 (0.53%)     0/757 (0.00%)  
Colonic obstruction † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Gastric ulcer † 1    
# participants affected / at risk     2/761 (0.26%)     3/757 (0.40%)  
Gastrointestinal haemorrhage † 1    
# participants affected / at risk     8/761 (1.05%)     7/757 (0.92%)  
Melaena † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Mouth ulceration † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Peptic ulcer † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Abdominal pain † 1    
# participants affected / at risk     6/761 (0.79%)     3/757 (0.40%)  
Diverticular perforation † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Duodenal ulcer haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Duodenal ulcer perforation † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Gastric ulcer perforation † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Gastrointestinal ulcer † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Haematochezia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Intestinal perforation † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Proctitis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Rectal haemorrhage † 1    
# participants affected / at risk     8/761 (1.05%)     5/757 (0.66%)  
Diarrhoea † 1    
# participants affected / at risk     44/761 (5.78%)     10/757 (1.32%)  
Dysphagia † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Enterovesical fistula † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Intestinal obstruction † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Oesophagitis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Reflux gastritis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Subileus † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Anal fistula † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Gastrooesophageal reflux disease † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Intra-abdominal haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Periodontal disease † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Volvulus † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Anal fissure † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Lower gastrointestinal haemorrhage † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Megacolon † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Proctalgia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Toothache † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Vomiting † 1    
# participants affected / at risk     14/761 (1.84%)     10/757 (1.32%)  
General disorders      
Chest pain † 1    
# participants affected / at risk     9/761 (1.18%)     8/757 (1.06%)  
Pyrexia † 1    
# participants affected / at risk     29/761 (3.81%)     14/757 (1.85%)  
Face oedema † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Mucosal inflammation † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Oedema † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Spinal pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Death † 1    
# participants affected / at risk     3/761 (0.39%)     3/757 (0.40%)  
Multi-organ failure † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Device occlusion † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Generalised oedema † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Disease progression † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Malaise † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Performance status decreased † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Asthenia † 1    
# participants affected / at risk     13/761 (1.71%)     7/757 (0.92%)  
Chills † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Influenza like illness † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Localised oedema † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Sudden death † 1    
# participants affected / at risk     0/761 (0.00%)     3/757 (0.40%)  
Fatigue † 1    
# participants affected / at risk     15/761 (1.97%)     9/757 (1.19%)  
General physical health deterioration † 1    
# participants affected / at risk     3/761 (0.39%)     1/757 (0.13%)  
Hyperthermia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Oedema peripheral † 1    
# participants affected / at risk     6/761 (0.79%)     4/757 (0.53%)  
Pain † 1    
# participants affected / at risk     7/761 (0.92%)     9/757 (1.19%)  
Hepatobiliary disorders      
Cholecystitis acute † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hepatic pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hepatotoxicity † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Cholelithiasis † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Cholecystitis † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Immune system disorders      
Hypersensitivity † 1    
# participants affected / at risk     3/761 (0.39%)     1/757 (0.13%)  
Anaphylactic reaction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Drug hypersensitivity † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Infections and infestations      
Erysipelas † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Infectious peritonitis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Neutropenic sepsis † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Respiratory tract infection † 1    
# participants affected / at risk     4/761 (0.53%)     1/757 (0.13%)  
Staphylococcal sepsis † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Upper respiratory tract infection † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Bronchitis † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Endocarditis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Influenza † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Lower respiratory tract infection † 1    
# participants affected / at risk     5/761 (0.66%)     0/757 (0.00%)  
Pyelonephritis acute † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Urosepsis † 1    
# participants affected / at risk     1/761 (0.13%)     4/757 (0.53%)  
Abscess intestinal † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Bacteraemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Candidiasis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Cellulitis † 1    
# participants affected / at risk     9/761 (1.18%)     3/757 (0.40%)  
Cellulitis of male external genital organ † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Diverticulitis † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Lobar pneumonia † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Peritonitis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Tooth infection † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Cystitis † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Fungal oesophagitis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Herpes zoster † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Neutropenic infection † 1    
# participants affected / at risk     3/761 (0.39%)     3/757 (0.40%)  
Oesophageal infection † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Oral candidiasis † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Perirectal abscess † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Pneumonia † 1    
# participants affected / at risk     32/761 (4.20%)     22/757 (2.91%)  
Scrotal abscess † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Anal abscess † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Bronchopneumonia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Clostridial infection † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Gangrene † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Gastrointestinal infection † 1    
# participants affected / at risk     4/761 (0.53%)     1/757 (0.13%)  
Infective exacerbation of chronic obstructive airways disease † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Pneumonia streptococcal † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Septic shock † 1    
# participants affected / at risk     9/761 (1.18%)     3/757 (0.40%)  
Balanoposthitis infective † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Clostridium difficile colitis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Device related infection † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Device related sepsis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Gastroenteritis † 1    
# participants affected / at risk     3/761 (0.39%)     3/757 (0.40%)  
Sepsis † 1    
# participants affected / at risk     6/761 (0.79%)     6/757 (0.79%)  
Urinary tract infection † 1    
# participants affected / at risk     10/761 (1.31%)     7/757 (0.92%)  
Appendicitis † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Empyema † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Infection † 1    
# participants affected / at risk     8/761 (1.05%)     4/757 (0.53%)  
Lung infection † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Injury, poisoning and procedural complications      
Clavicle fracture † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Femur fracture † 1    
# participants affected / at risk     2/761 (0.26%)     2/757 (0.26%)  
Joint injury † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Procedural complication † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Spinal fracture † 1    
# participants affected / at risk     0/761 (0.00%)     3/757 (0.40%)  
Fracture † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Gastroenteritis radiation † 1    
# participants affected / at risk     4/761 (0.53%)     1/757 (0.13%)  
Overdose † 1    
# participants affected / at risk     11/761 (1.45%)     6/757 (0.79%)  
Contusion † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Infusion related reaction † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Multiple fractures † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Gastrointestinal anastomotic leak † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Lumbar vertebral fracture † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Upper limb fracture † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Fall † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Femoral neck fracture † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Hip fracture † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Lower limb fracture † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Spinal compression fracture † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Tracheal obstruction † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Accidental overdose † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Anastomotic leak † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Rib fracture † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Venous injury † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Ulna fracture † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Thoracic vertebral fracture † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Investigations      
Haemoglobin † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Urine output decreased † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Aspartate aminotransferase increased † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Blood creatinine increased † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Clostridium test positive † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
General physical condition abnormal † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Neutrophil count † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Bone marrow myelogram abnormal † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Alanine aminotransferase increased † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Eastern Cooperative Oncology Group performance status worsened † 1    
# participants affected / at risk     3/761 (0.39%)     0/757 (0.00%)  
Platelet count decreased † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Weight decreased † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Haemoglobin decreased † 1    
# participants affected / at risk     9/761 (1.18%)     3/757 (0.40%)  
Neutrophil count decreased † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Transaminases increased † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Metabolism and nutrition disorders      
Fluid overload † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Metabolic acidosis † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Decreased appetite † 1    
# participants affected / at risk     3/761 (0.39%)     4/757 (0.53%)  
Dehydration † 1    
# participants affected / at risk     21/761 (2.76%)     11/757 (1.45%)  
Hypokalaemia † 1    
# participants affected / at risk     3/761 (0.39%)     2/757 (0.26%)  
Hypomagnesaemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hyponatraemia † 1    
# participants affected / at risk     2/761 (0.26%)     3/757 (0.40%)  
Hypophagia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hypocalcaemia † 1    
# participants affected / at risk     4/761 (0.53%)     6/757 (0.79%)  
Hypoglycaemia † 1    
# participants affected / at risk     3/761 (0.39%)     4/757 (0.53%)  
Hypophosphataemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hypercalcaemia † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Hyperglycaemia † 1    
# participants affected / at risk     2/761 (0.26%)     3/757 (0.40%)  
Malnutrition † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Hyperkalaemia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Tumour lysis syndrome † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Musculoskeletal and connective tissue disorders      
Back pain † 1    
# participants affected / at risk     7/761 (0.92%)     12/757 (1.59%)  
Musculoskeletal pain † 1    
# participants affected / at risk     1/761 (0.13%)     3/757 (0.40%)  
Pathological fracture † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Muscle spasms † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Systemic lupus erythematosus † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Groin pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Arthralgia † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Fistula † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Hypercreatinaemia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Muscular weakness † 1    
# participants affected / at risk     3/761 (0.39%)     4/757 (0.53%)  
Osteonecrosis of jaw † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Bone pain † 1    
# participants affected / at risk     4/761 (0.53%)     7/757 (0.92%)  
Flank pain † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Neck pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Osteoarthritis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Osteonecrosis † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Pain in extremity † 1    
# participants affected / at risk     3/761 (0.39%)     3/757 (0.40%)  
Musculoskeletal chest pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Metastases to meninges † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Metastasis † 1    
# participants affected / at risk     2/761 (0.26%)     2/757 (0.26%)  
Prostate cancer † 1    
# participants affected / at risk     2/761 (0.26%)     3/757 (0.40%)  
Cancer pain † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Colorectal cancer recurrent † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Metastatic squamous cell carcinoma † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Neoplasm progression † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Adenosquamous cell lung cancer † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Colorectal cancer † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Lip and/or oral cavity cancer † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Basal cell carcinoma † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Meningioma † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Metastatic neoplasm † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Astrocytoma malignant † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Prostate cancer metastatic † 1    
# participants affected / at risk     9/761 (1.18%)     10/757 (1.32%)  
Rectal cancer † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Squamous cell carcinoma of skin † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Neoplasm malignant † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Renal neoplasm † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Non-small cell lung cancer † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Nervous system disorders      
Cerebral ischaemia † 1    
# participants affected / at risk     3/761 (0.39%)     0/757 (0.00%)  
IIIrd nerve disorder † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Syncope † 1    
# participants affected / at risk     4/761 (0.53%)     5/757 (0.66%)  
Aphasia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Ataxia † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Headache † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Cerebrovascular accident † 1    
# participants affected / at risk     2/761 (0.26%)     4/757 (0.53%)  
Encephalitis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Ischaemic stroke † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Carotid artery stenosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Monoplegia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Motor dysfunction † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Paraparesis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Cerebral haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Convulsion † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Dizziness † 1    
# participants affected / at risk     1/761 (0.13%)     2/757 (0.26%)  
Peripheral motor neuropathy † 1    
# participants affected / at risk     1/761 (0.13%)     4/757 (0.53%)  
Depressed level of consciousness † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Haemorrhage intracranial † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Somnolence † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Spinal cord compression † 1    
# participants affected / at risk     4/761 (0.53%)     6/757 (0.79%)  
Transient ischaemic attack † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Central nervous system haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Cerebral haematoma † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Neuralgia † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Coma † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Dysarthria † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Intracranial pressure increased † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Nerve root compression † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Peripheral sensory neuropathy † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Psychiatric disorders      
Anxiety † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Depression suicidal † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Confusional state † 1    
# participants affected / at risk     6/761 (0.79%)     2/757 (0.26%)  
Disorientation † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Mental status changes † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Agitation † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Psychotic disorder † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Renal and urinary disorders      
Renal disorder † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Haematuria † 1    
# participants affected / at risk     10/761 (1.31%)     18/757 (2.38%)  
Urethral stenosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Urinary incontinence † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Bladder outlet obstruction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Haemoglobinuria † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Haemorrhage urinary tract † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Hydronephrosis † 1    
# participants affected / at risk     6/761 (0.79%)     3/757 (0.40%)  
Renal failure † 1    
# participants affected / at risk     5/761 (0.66%)     5/757 (0.66%)  
Urinary bladder polyp † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Bladder obstruction † 1    
# participants affected / at risk     3/761 (0.39%)     3/757 (0.40%)  
Obstructive uropathy † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Renal impairment † 1    
# participants affected / at risk     0/761 (0.00%)     3/757 (0.40%)  
Urogenital haemorrhage † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Bladder neck obstruction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Nephrotic syndrome † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Renal colic † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Renal failure acute † 1    
# participants affected / at risk     8/761 (1.05%)     4/757 (0.53%)  
Urinary retention † 1    
# participants affected / at risk     9/761 (1.18%)     9/757 (1.19%)  
Urinary tract obstruction † 1    
# participants affected / at risk     3/761 (0.39%)     2/757 (0.26%)  
Dysuria † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Ureteric obstruction † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Ureteric stenosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Urinary bladder haemorrhage † 1    
# participants affected / at risk     3/761 (0.39%)     1/757 (0.13%)  
Reproductive system and breast disorders      
Benign prostatic hyperplasia † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Testicular mass † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Penile pain † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Oedema genital † 1    
# participants affected / at risk     2/761 (0.26%)     1/757 (0.13%)  
Prostatic obstruction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Respiratory, thoracic and mediastinal disorders      
Chronic obstructive pulmonary disease † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Dyspnoea † 1    
# participants affected / at risk     21/761 (2.76%)     10/757 (1.32%)  
Hypoxia † 1    
# participants affected / at risk     3/761 (0.39%)     1/757 (0.13%)  
Pleural effusion † 1    
# participants affected / at risk     18/761 (2.37%)     1/757 (0.13%)  
Productive cough † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Acute respiratory distress syndrome † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Interstitial lung disease † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Lung infiltration † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Pneumothorax † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Pulmonary embolism † 1    
# participants affected / at risk     5/761 (0.66%)     17/757 (2.25%)  
Pulmonary hypertension † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Respiratory failure † 1    
# participants affected / at risk     7/761 (0.92%)     2/757 (0.26%)  
Acute pulmonary oedema † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Alveolitis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Dyspnoea exertional † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Pneumonitis † 1    
# participants affected / at risk     7/761 (0.92%)     7/757 (0.92%)  
Pulmonary congestion † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Pulmonary oedema † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Cough † 1    
# participants affected / at risk     3/761 (0.39%)     1/757 (0.13%)  
Lung disorder † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Pulmonary venous thrombosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Skin and subcutaneous tissue disorders      
Pyoderma gangrenosum † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Drug eruption † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Peau d'orange † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Rash † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Vascular disorders      
Haemorrhage † 1    
# participants affected / at risk     1/761 (0.13%)     1/757 (0.13%)  
Peripheral vascular disorder † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Thrombophlebitis superficial † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Circulatory collapse † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Phlebitis † 1    
# participants affected / at risk     0/761 (0.00%)     2/757 (0.26%)  
Vasculitis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Deep vein thrombosis † 1    
# participants affected / at risk     1/761 (0.13%)     10/757 (1.32%)  
Embolism † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Hypotension † 1    
# participants affected / at risk     3/761 (0.39%)     8/757 (1.06%)  
Vena cava thrombosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Haematoma † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Hypertension † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Thrombosis † 1    
# participants affected / at risk     2/761 (0.26%)     0/757 (0.00%)  
Aortic dissection † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Infarction † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Jugular vein thrombosis † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Shock haemorrhagic † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Venous thrombosis † 1    
# participants affected / at risk     1/761 (0.13%)     0/757 (0.00%)  
Venous thrombosis limb † 1    
# participants affected / at risk     0/761 (0.00%)     1/757 (0.13%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 15.0




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information